The 2023 LSX Congress in Boston, MA, heard the views of top-tier medtechs BD, GE HealthCare and Merit Medical as they outlined sustainability compliance strategies and goal setting mechanisms, as summarized in this latest contribution to In Vivo’s rolling series on “The E in ESG.”
• Source: Shutterstock (Shutterstock)
Environmental, social and governance (ESG) issues and compliance with sustainability initiatives, be they mandatory or voluntary, must be the focus of all areas of a medtech’s business.
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.